Skip to main content
. 2014 Sep 21;2014:437971. doi: 10.1155/2014/437971

Table 4.

Calculated age-specific incidence rates, crude rates, and ASR (World), females, Egypt 2008–2011.

Site 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75+ Crude rate ASR %
Lip 0.3 1.4 0.8 0.5 1.6 0.8 1.3 4.7 0.2 0.4 0.21%
Tongue 0.5 0.4 0.4 1.2 0.7 15.4 0.3 0.5 0.26%
Mouth 0.1 0.1 0.3 1.0 0.8 0.5 1.4 2.9 6.1 2.7 0.3 0.5 0.28%
Salivary glands 0.3 0.7 2.9 0.7 2.9 0.2 0.3 0.18%
Tonsil 2.2 1.4 0.1 0.04%
Other oropharynx 0.3 0.7 0.8 0.1 0.04%
Nasopharynx 0.1 0.1 1.6 0.1 0.1 0.06%
Hypopharynx 0.2 0.4 0.3 1.0 0.9 0.5 1.1 0.2 0.2 0.16%
Pharynx unspec. 0.2 0.01%
Esophagus 0.2 2.0 1.3 0.8 3.7 11.1 10.6 9.2 5.4 0.9 1.5 0.79%
Stomach 0.1 2.0 1.4 3.1 5.1 5.7 5.1 9.7 16.3 18.7 14.8 1.8 2.7 1.65%
Small intestine 0.4 1.9 1.7 1.4 5.2 4.8 0.4 0.5 0.32%
Colon 0.5 0.5 1.0 2.4 2.9 7.9 9.4 7.9 10.4 25.2 16.2 29.4 2.5 3.8 2.28%
Rectum 0.1 1.1 1.2 0.7 1.9 1.7 1.9 2.9 3.0 3.9 4.4 5.4 0.8 1.1 0.72%
Anus 0.2 0.3 0.5 1.6 1.3 0.1 0.1 0.09%
Liver 1.0 0.5 0.9 2.0 3.3 12.5 25.2 43.2 89.3 129.3 143.9 167.9 150.4 15.1 24.4 13.54%
Gallbladder and so forth 0.3 0.5 0.5 0.3 1.3 2.5 3.3 2.2 3.7 6.9 6.0 0.6 0.9 0.55%
Pancreas 0.4 0.5 0.6 3.0 3.4 8.6 9.0 18.7 24.4 19.5 1.6 2.6 1.41%
Nose, sinuses and so forth 0.1 0.3 0.7 1.2 1.2 5.4 0.3 0.4 0.23%
Larynx 0.3 1.0 2.0 3.0 3.0 2.1 0.3 0.4 0.23%
Trachea, Bronchus, Lung 0.7 0.1 0.1 0.5 2.0 1.0 1.5 1.7 6.9 12.3 11.7 15.1 11.3 35.9 38.0 3.0 4.5 2.70%
Other Thoracic organs 0.8 1.7 1.6 2.6 1.6 3.0 1.3 10.7 0.5 0.7 0.42%
Bone 0.7 0.1 1.1 2.0 1.4 0.7 0.7 2.2 0.9 2.3 6.5 6.7 12.0 4.5 2.6 16.9 2.0 2.5 1.80%
Melanoma of skin 0.6 2.2 4.4 0.1 0.2 0.10%
Other skin 0.3 0.2 0.4 0.5 2.0 2.7 1.2 8.6 10.4 14.0 14.9 11.8 1.4 2.2 1.24%
Mesothelioma 1.2 0.5 3.0 1.1 4.8 0.2 0.3 0.17%
Kaposi sarcoma 0.8 0.01%
Connective, Soft tissue 1.2 0.3 0.7 0.4 1.5 2.1 1.7 1.2 2.0 2.0 2.9 2.4 6.2 3.9 3.1 13.4 1.6 1.9 1.42%
Breast 3.1 9.5 29.2 49.0 86.0 106.2 136.0 172.9 177.4 166.3 138.7 148.6 35.8 48.8 32.04%
Vulva 0.1 0.1 0.3 1.0 0.8 1.4 0.1 0.1 0.09%
Vagina 1.0 3.0 3.3 1.4 0.2 0.3 0.14%
Cervix Uteri 0.2 0.2 0.6 3.6 6.5 9.1 8.3 10.5 1— 9.4 1.3 2.0 1.17%
Corpus Uteri 0.5 0.2 0.6 1.3 0.7 8.1 4.3 3.0 3.0 12.1 0.7 1.1 0.62%
Uterus unspec. 0.5 1.2 0.4 0.7 0.5 1.8 1.6 11.1 9.5 21.5 20.4 31.4 21.2 2.5 3.9 2.27%
Ovary 0.5 0.4 0.8 1.5 1.5 3.3 8.7 17.2 20.3 24.0 19.6 17.2 2— 26.3 4.6 6.3 4.12%
Other female genital 0.3 1.3 2.1 0.1 0.1 0.05%
Placenta 0.4 0.03%
Kidney 1.5 0.1 0.5 0.8 0.5 0.6 2.9 2.3 1.0 10.4 10.7 1.3 7.3 1.1 1.6 0.97%
Renal pelvis 0.3 0.6 0.2 0.7 0.4 0.5 1.6 0.8 0.2 0.3 0.19%
Ureter 0.00%
Bladder 0.1 0.2 0.2 0.7 0.8 5.3 8.2 18.6 20.2 37.8 43.6 53.9 3.3 5.5 2.96%
Other urinary organs 2.2 0.1 0.03%
Eye 0.1 0.3 0.5 1.2 0.7 0.8 1.4 0.2 0.2 0.14%
Brain, Nervous tissue 3.3 2.1 1.9 0.8 2.9 0.7 4.5 6.5 6.6 9.5 11.3 12.1 31.4 26.3 33.1 72.2 5.8 8.0 5.18%
Thyroid 2.7 2.8 10.2 7.2 6.4 9.7 10.2 11.0 9.0 2.6 10.4 14.2 3.7 4.3 3.28%
Adrenal gland 1.5 0.1 1.2 1.4 0.2 0.3 0.20%
Other endocrine 0.1 0.1 0.1 0.3 0.5 0.3 0.3 0.4 1.0 0.7 0.8 0.2 0.2 0.19%
Hodgkin disease 0.6 0.4 1.9 1.3 0.4 1.2 0.7 0.6 0.4 1.2 3.8 0.8 0.8 0.70%
Non-Hodgkin lymphoma 0.9 0.7 1.1 0.8 1.2 1.7 3.3 3.8 8.6 16.0 23.4 24.1 16.8 31.3 36.7 4.2 6.1 3.80%
Immunoproliferative dis. 0.00%
Multiple myeloma 0.6 1.4 0.8 1.2 2.3 4.4 6.1 2.7 0.4 0.6 0.34%
Lymphoid leukemia 2.0 0.7 0.9 0.4 0.5 0.7 0.7 1.4 1.0 2.7 1.7 2.8 3.9 4.4 1.0 1.2 0.93%
Myeloid Leukemia 0.5 0.3 0.7 0.2 1.5 1.5 1.4 1.0 0.9 0.7 4.0 3.1 6.8 7.5 4.9 1.3 1.6 1.14%
Leukemia unspec. 0.4 0.7 0.7 1.3 0.9 1.7 1.5 0.7 1.4 2.7 3.3 5.5 6.1 8.3 7.4 14.8 1.7 2.2 1.55%
Other & unspecified 1.4 0.9 1.9 1.7 2.4 3.9 4.6 5.5 9.6 12.5 23.8 37.3 39.9 42.1 42.6 70.5 7.7 10.8 6.93%

All sites Total 16.1 7.8 10.1 11.4 22.4 34.9 69.7 95.2 163.7 255.3 359.1 506.5 633.7 665.8 715.9 850.5 111.7 159.1 100.00%
All sites but C44# 15.8 7.8 10.1 11.2 22.4 34.6 69.3 95.2 161.6 252.5 357.9 497.8 623.3 651.8 701.0 838.7 110.3 157.0 98.76%

#Incidence rates do not include nonmelanoma skin cancer.

HHS Vulnerability Disclosure